David Benito Laorga’s Haemophilia Team Hosts Hemosfera
David Benito Laorga, Business Unit Director and Management Team Member Novo Nordisk Spanish Affiliate, shared on LinkedIn:
”This weekend, our haemophilia team hosted Hemosfera, a truly innovative meeting centered on a new treatment with the potential to reduce treatment burden, improve quality of life, and open new possibilities for patients and families.
I’m especially proud of the team behind the scenes.
From concept to execution, this event was powered by strong ownership, deep commitment, and a shared conviction that meaningful innovation requires doing things differently—and doing them well.
This is what high-performing teams look like.
My sincere thanks as well to all the speakers for the depth and quality of the discussions.
Your insights and engagement were critical to making this a truly valuable and impactful event.
Proud of the team. Motivated by the impact we can create for patients.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?